Synopsis:
Sakar Healthcare jumped sharply after securing 9 new approvals for its oncology drugs across Europe and emerging markets, taking the total to 11. This move strengthens its global presence and opens new export opportunities for its cancer treatment portfolio.
The shares of this leading pharmaceutical company are in focus after receiving new approval for its injection to treat cancer. In this article, we will dive more into the details and their significance.
With a market capitalization of Rs 809 crore, the shares of Sakar Healthcare Ltd made a day high of Rs 376.60 per share, up by 4 percent from its day’s low price of Rs 360.55 per share. Over the past five years, the stock has delivered a robust return of 333 percent, outperforming NIFTY 50’s return of 108 percent.
About the Announcement
Sakar Healthcare, through a stock exchange filing, announced that it obtained 9 new marketing approvals for its oncology (cancer) medicines, thereby bringing the total number of approvals to 11 in different countries of Europe and emerging markets. The approval documents cover the essential drugs like Carboplatin, Docetaxel, Irinotecan, Gemcitabine, Tamoxifen, and Abiraterone, which are the most widely used in the treatment of various kinds of cancer.
These approvals will empower Sakar to deliver its anti-cancer products to countries in Europe, Latin America, and Southeast Asia. According to the company, these products are manufactured at its own EU-GMP-certified facility, and it is planning to get more such approvals in the next few months, thereby increasing its export potential and consolidating its presence globally in the oncology sector.
Financial Highlights
Sakar Healthcare’s revenue for Q1 FY26 came in at Rs 52.74 crore, registering a 28 percent growth from Rs 41.15 crore in the same quarter last year. Coming to its profitability, the company reported an impressive net profit growth of 94 percent to Rs 4.67 crore in Q1 FY26 as compared to Rs 2.41 crore in Q1 FY25.
The stock delivered a poor ROE and ROCE of 6.48 percent and 8.54 percent respectively, and is currently trading at a high P/E of 42x as compared to its industry average of 33x.
Sakar Healthcare Limited is a pharmaceutical company based in India that focuses on researching, manufacturing, and marketing a diverse array of medicines. Their product lineup includes tablets, capsules, syrups, injections, and dry powders, catering to various health needs like pain relief, infections, mental health, digestion, and more. They also export their products to regions including Southeast Asia, Africa, the MENA area, and the United States.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
